TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
PR Newswire•04/11/2026•09:15 ET
0
Key Highlights
- ➤TuHURA will present three DOR research posters at ASH December 12-15, 2026
- ➤DOR inhibition reduced Cxcl10, Saa3 and Acod1 gene expression in MDSCs
- ➤DOR research supports potential immune-modulating ADC applications in cancer and autoimmune disease
- ➤TuHURA initiated a randomized Phase 3 IFx-2.0 plus Keytruda trial in Merkel Cell Carcinoma
Expert Statements
James Bianco, President and Chief Executive Officer of TuHURA Biosciences
“We continue to be impressed by uncovering the central role the DOR plays in proliferation, recruitment and immune suppressing capabilities across MDSCs, T regs and M2 macrophages, the 3 most important naturally occurring immune suppressing cells in the body.”
James Bianco, President and Chief Executive Officer of TuHURA Biosciences
“In addition to providing information critical to multiple patent submissions, the data underscore the breadth of the potential therapeutic applications for DOR technology in the development of a first new class of non-tumor targeting, immune modulating ADCs.”
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition PR Newswire
Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages
Get started
Create a free account to read the full story.